Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Fineline Cube Sep 8, 2026
Company Drug

Bristol-Myers Squibb Wins FDA Approval for Opdivo-Yervoy Combo in First-Line HCC Treatment

Fineline Cube Apr 14, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval from the US Food and...

Company Deals

Jiangxi Institute of Biological Products Files for Hong Kong IPO Amid Strong Market Position

Fineline Cube Apr 14, 2025

Jiangxi Institute of Biological Products Inc., China’s largest provider and exporter of human tetanus antitoxin...

Company Deals Drug

Zhaoke Ophthalmology Launches Phase II Study for Brimochol PF in Presbyopia Treatment

Fineline Cube Apr 14, 2025

Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the initiation of a multi-center, double-blinded, crossover, placebo-controlled...

Company Drug

CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of SYH2046 in Heart Failure

Fineline Cube Apr 14, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Amgen’s Imdelltra Shows Positive Phase III Results in Small Cell Lung Cancer

Fineline Cube Apr 14, 2025

US biotech giant Amgen (NASDAQ: AMGN) has announced positive results from the global Phase III...

Company Medical Device

Shanghai Microport EP Medtech Secures NMPA Fast-Track Designation for EasyEcho Catheter

Fineline Cube Apr 14, 2025

China’s Shanghai Microport EP Medtech Co., Ltd (SHA: 688351) has announced that it has received...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-3792 and HRS-9190

Fineline Cube Apr 14, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received separate...

Company Drug

Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer

Fineline Cube Apr 14, 2025

US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an...

Company Drug

Tasly Pharma Gains NMPA Green Light for CAR-T Therapy Clinical Study in Recurrent Glioblastoma

Fineline Cube Apr 14, 2025

China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received approval from...

Company Drug

CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin

Fineline Cube Apr 14, 2025

China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received...

Company

Novartis Announces USD 23 Billion Investment to Expand U.S. Manufacturing and R&D Hubs

Fineline Cube Apr 11, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced plans to invest USD 23 billion over...

Company Drug

Juventas Cell Therapy Secures China Clinical Trial Approval for Inaticabtagene Autoleucel in AIHA

Fineline Cube Apr 11, 2025

Chinese firm Juventas Cell Therapy Ltd has obtained tacit clinical trial approval in China for...

Company Drug

Belief BioMed and Takeda Win NMPA Approval for China’s First Hemophilia B Gene Therapy

Fineline Cube Apr 11, 2025

China-based gene therapy specialist Belief BioMed Inc. and Takeda’s (NYSE: TAK, TYO: 4502) China unit...

Company Drug

Zai Lab’s Partner argenx Secures FDA Approval for Vygart Hytrulo Prefilled Syringe in gMG and CIDP

Fineline Cube Apr 11, 2025

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) and its Dutch partner argenx SE (NASDAQ:...

Company Deals

Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology

Fineline Cube Apr 11, 2025

France’s Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG...

Company Deals Medical Device

INTCO Medical and JD Healthcare Partner to Innovate ‘Internet + Healthcare’ Service Models

Fineline Cube Apr 11, 2025

China-based INTCO Medical (SHE: 300677), a high-tech manufacturer of medical consumables and equipment, has entered...

Company Medical Device

KingstronBio’s Prostyle A Valve Gains NMPA Approval, Setting New Benchmark in Transcatheter Aortic Valve Replacement

Fineline Cube Apr 11, 2025

KingstronBio, a Changshu-based structural heart disease device manufacturer, has obtained marketing approval from China’s National...

Company Deals

iRegene Therapeutics Secures RMB 100 Million in Series B+ Financing to Advance iPSC Technology

Fineline Cube Apr 11, 2025

Wuhan-based iRegene Therapeutics, a pioneer in AI-powered, chemically induced cell therapies, has reportedly raised close...

Company

Novo Nordisk Invests BRL 6.4 Billion in Brazilian Manufacturing Expansion for Obesity Drugs

Fineline Cube Apr 11, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced a significant investment of BRL 6.4 billion...

Company Drug

Jemincare Group Announces NMPA Approval of Generic Clenil for Asthma Treatment

Fineline Cube Apr 11, 2025

China-based Jiangxi Jemincare Group has announced that it has received marketing approval from the National...

Posts pagination

1 … 230 231 232 … 717

Recent updates

  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
  • Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Company Deals

Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.